After receiving a green light from both U.S. and EU antitrust regulators, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent Inc. have been fulfilled. The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.   The acquisition of Catalent is part of Novo Nordisk’s broader strategy to expand its manufacturing capabilities and secure...